SCHEMBL3871815

SCHEMBL3871815

CC1(C)COB(c2ccc(CBr)cc2)OC1

nearest known ligand 0.40

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
SNCA P37840 1/20 0.40
LPL P06858 6/20 0.39
LIPG Q9Y5X9 6/20 0.39
F11 P03951 1/20 0.34
ESR2 Q92731 1/20 0.32
TRPA1 O75762 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4264297 0.84 SNCA (0.44) SNCALPLLIPGF11
SCHEMBL19865291 0.84 LPL (0.43) SNCALPLLIPGF11ESR2
SCHEMBL7709040 0.83 LPL (0.40) LPLLIPGF11ESR2
SCHEMBL15293463 0.82 SNCA (0.40) SNCALPLLIPGF11ESR2
SCHEMBL308421 0.80 LPL (0.41) SNCALPLLIPGTRPA1ALDH1A1
SCHEMBL5528199 0.79 SNCA (0.40) SNCALPLLIPGALDH1A1TSHR
SCHEMBL21090361 0.79 ESR1 (0.40) SNCALPLLIPGF11ESR2
SCHEMBL4257326 0.79 SNCA (0.48) SNCALPLLIPG
SCHEMBL7706050 0.79 TRPA1 (0.37) LPLLIPGTRPA1ALDH1A1TSHR
SCHEMBL25382357 0.78 LPL (0.36) LPLLIPGF11ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795008-B2 An organized, self-assembled monolayer (SAM) on a sensing surface of a sensor device for identifying at least one foreign material from environment; has a piezoelectric crystal element and a sensor M.S. TECH LTD. (IL) 2010-09-14 US disclosed
US-7795008-B2 An organized, self-assembled monolayer (SAM) on a sensing surface of a sensor device for identifying at least one foreign material from environment; has a piezoelectric crystal element and a sensor M.S. TECH LTD. (IL) 2010-09-14 US disclosed
EP-1833801-B9 INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS ALGRY QUIMICA S L (ES) 2009-02-25 EP disclosed
EP-1833801-B1 INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS ALGRY QUIMICA S L (ES) 2008-06-04 EP disclosed
EP-1833801-A2 INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS ALGRY QUIMICA, S.L (ES) 2007-09-19 EP disclosed
US-20070117983-A1 Sensitive and selective method and device for the detection of trace amounts of a substance DAYAGI YOHAI Y 2007-05-24 US disclosed
US-20070117983-A1 Sensitive and selective method and device for the detection of trace amounts of a substance DAYAGI YOHAI Y 2007-05-24 US disclosed
US-7159463-B2 Sensitive and selective method and device for the detection of trace amounts of a substance M.S. TECH LTD. (IL) 2007-01-09 US disclosed
US-7159463-B2 Sensitive and selective method and device for the detection of trace amounts of a substance M.S. TECH LTD. (IL) 2007-01-09 US disclosed
WO-2006067215-A2 INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS ALGRY QUÍMICA, S. L. (ES) 2006-06-29 WO disclosed
US-20040087842-A1 Fluorescent probes for saccharrides LAKOWICZ JOSEPH R (US) 2004-05-06 US disclosed
US-5420292-A Biphenyl-tetrazole intermediate compounds ZENECA LIMITED (GB) 1995-05-30 US disclosed
US-5294716-A Chemical process for making angiotesin II antagonist compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-03-15 US disclosed
US-5245035-A HETEROCYCLIC BORON COMPOUNDS AS INTERMEDIATES FOR ANGIOTENSIN II ANTAGONISTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-09-14 US disclosed
EP-0495626-A1 Process for the preparation of tetrazole derivatives ZENECA LIMITED (GB) 1992-07-22 EP disclosed
EP-0495627-A1 Boron compounds ZENECA LIMITED (GB) 1992-07-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117983-A1 Sensitive and selective method and device for the detection of trace amounts of a substance CRABP2, TMEM63A, RALA SNCA 1795/4885LPL 4544/4885LIPG 2584/4885
US-20040087842-A1 Fluorescent probes for saccharrides ST6GAL1, SLC5A1, CA6 SNCA 3593/4885LPL 4758/4885LIPG 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.